AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RIGEL PHARMACEUTICALS INC Director's Dealing 2025

Feb 7, 2025

32801_dirs_2025-02-06_7df7d95f-321b-4175-a1b0-cc68deb43b55.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2025-02-04

Reporting Person: Santos David A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-04	Common Stock	S	2125	$20.921	Disposed	53500	Direct
2025-02-05	Common Stock	S	1796	$21.926	Disposed	51704	Direct

Footnotes

F1: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person.